Cost-benefit analysis as an integral part of market access.
Cost-Benefit assessment will remain an integral part of health economics in the next few years. Not only is this information from international studies relevant, but so are the analyses specific to the German treatment environment.
Senior researchers at Xcenda play a vital role in the discussions on methodological standards, as evidenced by several leading authorships in the current health economic guidelines, known as "Hannoveraner Konsens".
The staff at Xcenda will consult with you regarding the most sensible and practical use of health economic evaluations. They rely on a broad knowledge base to be able to perform a goal-oriented health economic evaluation.